Institute for Systems Biology

Famed Scientist Lee Hood Will Co-Direct the Center for Phenomic Health at the Buck Institute

Retrieved on: 
Wednesday, September 27, 2023
Kyoto Prize in Basic Sciences, DNA, Kyoto Prize, National academy, Buck Institute for Research on Aging, Partnership, Systems biology, National Academy of Engineering, Ageing, Buck, National Medal, Research, Doctor of Philosophy, Institute for Systems Biology, Science, National Academy of Medicine, Human, Blood, Saliva, Biology, Information Innovation Office, National Medal of Science, Health, Human Genome Project, Distinguishing, Health information management, Professors in the United States, Disease, Pharmaceutical industry, MD, Medicine

NOVATO, Calif., Sept. 27, 2023 /PRNewswire/ -- The Buck Institute for Research on Aging and Phenome Health are joining forces in the quest to understand the biology of aging. Phenome Health, a Seattle-based nonprofit research organization led by CEO Lee Hood, MD, PhD, uses a data-driven approach to health and disease that integrates diverse types of biological big data. The new Center for Phenomic Health at the Buck will be co-led by Dr. Hood, who joins the Buck as Chief Innovation Officer and Distinguished Professor, and Eric Verdin, MD, Buck President and CEO.

Key Points: 
  • The new Center for Phenomic Health at the Buck will be co-led by Dr.
  • Hood, who joins the Buck as Chief Innovation Officer and Distinguished Professor, and Eric Verdin, MD, Buck President and CEO.
  • Hood is a world-renowned scientist whose technology (automated DNA sequencing) paved the way for the Human Genome Project.
  • The opportunity to form a Center with Lee Hood and his Phenome Health team will be transformational for the Buck," said Dr. Verdin.

COVID-19 Vaccines and Boosters Are Essential for Maternal-Fetal Health

Retrieved on: 
Monday, September 25, 2023
COVID-19, Research, Women, Baby, Maternity, Other Health, Health, Consumer, General Health, Science, Vaccine, Pregnancy, Interview, Vaccination, Systems biology, Multimedia, COVID, RNA, Doctor of Philosophy, Associate, CDC, Digital health, Institute for Systems Biology, MD, Patient, Risk, Preterm birth, Stillbirth, FDA, Woman, Birth control

In light of the recent FDA and CDC decision to approve two updated messenger RNA COVID-19 booster shots, it is imperative to alert the pregnant population of the importance and effectiveness of these vaccines and boosters.

Key Points: 
  • In light of the recent FDA and CDC decision to approve two updated messenger RNA COVID-19 booster shots, it is imperative to alert the pregnant population of the importance and effectiveness of these vaccines and boosters.
  • This press release features multimedia.
  • Pregnant people who are vaccinated are less likely to contract COVID-19 than unvaccinated pregnant people, and those vaccinated and boosted are less likely to get COVID than those who are vaccinated only.
  • Journalists: If you would like to speak with one of the paper’s authors listed above, please contact Joe Myxter ( [email protected] ), who can coordinate an interview.

ISB Researchers Find a Chink in the Armor of Tuberculosis Pathogen

Retrieved on: 
Tuesday, August 29, 2023
Research, Technology, Infectious Diseases, Genetics, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Science, Senior, Systems biology, Bill & Melinda Gates Foundation, TB, National Institute of Allergy and Infectious Diseases, Infection, Cell wall, Multimedia, Photograph, ISB, MTB, Institute for Systems Biology, Tuberculosis, Paper, Environment, Mycobacterium tuberculosis, Cell Reports, Vaccine, Pharmaceutical industry

Mycobacterium tuberculosis (Mtb) is the pathogen that causes tuberculosis (TB), the world’s deadliest infectious disease.

Key Points: 
  • Mycobacterium tuberculosis (Mtb) is the pathogen that causes tuberculosis (TB), the world’s deadliest infectious disease.
  • Mtb is so successful and harmful because it can adapt to different conditions inside our bodies, allowing it to evade treatment.
  • When the network is disrupted, researchers found that Mtb’s cells are unable to properly divide, compromising their cell wall – a key defense mechanism.
  • EGRIN 2.0 identified a signaling system called MtrA that helps the pathogen grow in response to signals from a host’s body.

BlueNalu Establishes Scientific Advisory Board to Support Scale-Up and Consumer Launch

Retrieved on: 
Wednesday, October 26, 2022
Manufacturing, Environmental Issues, Specialty, Organic Food, Food, Beverage, Agriculture, Natural Resources, Retail, Environment, Engineering, Sustainability, Venus, Goal, Doctor of Philosophy, United Nations Global Compact, CSO, Development, Process, Systems biology, Growth, Procter & Gamble, Review, Human Genome Sciences, Sutro Biopharma, Cacao, Institute for Systems Biology, Iran National Science Foundation, Drug resistance, BioMarin Pharmaceutical, Diosynth, Multimedia, Institute, Wine, Urology, Gillette, Technology, SVP, SAB, Department, Â, CEO, E & J Gallo Winery, National Science Foundation, Food, Climate change, Ministry of Energy, PepsiCo, Nitin, Coffee, Solution, Engineering, Management, Fine chemical, Midas

BlueNalu, a global leader in the development of cell-cultured seafood, today announced the formation of its scientific advisory board (SAB) to support its next stages of growth.

Key Points: 
  • BlueNalu, a global leader in the development of cell-cultured seafood, today announced the formation of its scientific advisory board (SAB) to support its next stages of growth.
  • View the full release here: https://www.businesswire.com/news/home/20221026005451/en/
    BlueNalu's inaugural scientific advisory board members: Jennifer Jo Wiseman (top left); Geoffrey Margolis, Sc.D.
  • Throughout her 35-year long career, her work has centered around the consumer to create products that build better lives for people.
  • For BlueNalu images related to this release and to learn more about its esteemed scientific advisory board members, click here .

Gladstone Institutes Joins the Parker Institute for Cancer Immunotherapy Network

Retrieved on: 
Wednesday, September 28, 2022
Institute, Icahn School of Medicine at Mount Sinai, University, MD Anderson Cancer Center, Department, Dana–Farber Cancer Institute, Twitter, Mount Sinai, MD, University of California, San Francisco, CRISPR, Genetic engineering, LinkedIn, Systems biology, Institute for Systems Biology, Stanford University School of Medicine, Intellectual property, Washington University School of Medicine, Marson, Partnership, Industry, Immunotherapy, Program, Patient, Cancer, City, Multimedia, Organization, Gladstone Institutes, Technology, Memorial Sloan Kettering Cancer Center, Doctor of Philosophy, Pathology, SAN, Stanford School, Genomics, Research, DNA, Silicon, Medicine, Broad Institute, Immune system, Fred Hutchinson Cancer Research Center, Network, City of Hope, UCSF, Vaccine, Management, Pharmaceutical industry, William Ewart Gladstone

SAN FRANCISCO, Sept. 28, 2022 /PRNewswire/ -- Gladstone Institutes has partnered with the Parker Institute for Cancer Immunotherapy (PICI), the leading network of immuno-oncology expertise in the world, to establish a new research center focused on using genomics and CRISPR technology to program the human immune system to treat cancer.

Key Points: 
  • Alex Marson, MD, PhD, director of the Gladstone-UCSF Institute of Genomic Immunology and a professor of medicine at UC San Francisco, will serve as director of the new Parker Institute for Cancer Immunotherapy at Gladstone Institutes.
  • In 2019, backed by an initial investment of $25 million from PICI, Marson and PICI Network scientific leaders from UCSF, the University of Pennsylvania, Broad Institute, and Dana-Farber Cancer Institute co-founded cancer cell therapy developer ArsenalBio.
  • Parker Institute for Cancer Immunotherapy: James Goodwin| Associate Director, Communications| [email protected]
    To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impactunsolved diseases.
  • The Parker Institute for Cancer Immunotherapy (PICI) is radically changing how cancer research is done.

Empowering Tomorrow’s Great Minds in Cancer Research: The Parker Institute for Cancer Immunotherapy Awards up to $4.5 Million to Nine Early Career Researchers; Total of Over $19 Million Awarded to Date

Retrieved on: 
Wednesday, July 27, 2022
Research, Philanthropy, Continuing, General Health, University, Health, Foundation, Science, Education, Oncology, Silicon, Emma, University, Icahn School of Medicine at Mount Sinai, ESPN, Industry, Stanford University School of Medicine, Twitter, Memorial Sloan Kettering Cancer Center, Jim Valvano, CAR, Research, Parker, Institute for Systems Biology, Institute, Dana–Farber Cancer Institute, Learning, UCLA, City, Cell, Penn, Fred Hutchinson Cancer Research Center, Immunotherapy, Cancer, MSK, LinkedIn, Patient, Dana, University of California, San Francisco, Doctor of Philosophy, Washington University School of Medicine, Systems biology, Mount Sinai, Program, Informatics, MD Anderson Cancer Center, Stanford University, Mohammed V Foundation for Solidarity, Management, Pharmaceutical industry

PICI helps us further the V Foundations mission to fund accomplished young researchers bringing new techniques to combat cancer that warrant further exploration.

Key Points: 
  • PICI helps us further the V Foundations mission to fund accomplished young researchers bringing new techniques to combat cancer that warrant further exploration.
  • As part of the PICI Network, I will interact and share my ideas with some of the brightest minds in the field.
  • or Ph.D. degree and is ready to establish a laboratory or independent program in cancer immunotherapy.
  • The Parker Institute for Cancer Immunotherapy (PICI) is radically changing how cancer research is done.

The Parker Institute for Cancer Immunotherapy and Resilience Announce Strategic Alliance to Develop Next-Generation Cancer Therapies

Retrieved on: 
Wednesday, June 8, 2022
Other Manufacturing, Research, Genetics, Manufacturing, Other Health, Biotechnology, Pharmaceutical, Health, Science, Oncology, Science, IO, Â, Doctor of Science, Immunotherapy, Washington University School of Medicine, Research, Fred Hutchinson Cancer Research Center, Doctor of Philosophy, LinkedIn, Silicon, Stanford University School of Medicine, Cancer, Multimedia, Investment, Solution, Therapy, University, City, Patient, Memorial Sloan Kettering Cancer Center, Technology, Systems biology, Mount Sinai, Social media, Twitter, Industry, Dana–Farber Cancer Institute, Drug discovery, Dana, Institute for Systems Biology, Network Investigative Technique, Philosophy, Institute, Icahn School of Medicine at Mount Sinai, MD Anderson Cancer Center, University of California, San Francisco, Pharmaceutical industry, Resilience

Under the agreement, Resilience will also collaborate with PICI Network investigators on challenges related to biomanufacturing and novel treatment modalities.

Key Points: 
  • Under the agreement, Resilience will also collaborate with PICI Network investigators on challenges related to biomanufacturing and novel treatment modalities.
  • This alliance with PICI will demonstrate the power of new business models in finding and advancing cancer therapies.
  • Our goal is to ensure these therapies can be made at the quality and scale required to bring transformative immune therapies to people with cancer.
  • The Parker Institute for Cancer Immunotherapy (PICI) is radically changing how cancer research is done.

Gut Microbiome Composition Predictive of Patient Response to Statins

Retrieved on: 
Wednesday, May 11, 2022
Health, Diabetes, Research, Pharmaceutical, Science, Biotechnology, COVID-19, MED, Systems biology, Population, YouTube, Twitter, Metabolome, Blood, Stroke, Insulin resistance, Genome, Time, LDL, Patient, Paper, Clinical trial, Cancer, Marker beacon, Institute, Health, LinkedIn, Cholesterol, Ageing, ISB, Genetics, Infection, Bacteroides, Ruminococcaceae, Institute for Systems Biology, Risk, Multimedia, Pharmaceutical industry, Antibiotics, Facebook

View the full release here: https://www.businesswire.com/news/home/20220511005441/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220511005441/en/
    Researchers from Institute for Systems Biology have shown that different patient responses to statins can be explained by the variation in the human microbiome.
  • The research team found that the composition and diversity of the gut microbiome is predictive of the efficacy of statins and the magnitude of negative side effects.
  • The team also found that individuals with a Ruminococcaceae enriched microbiome were protected from the negative side effects of statins on insulin resistance while also showing a clear LDL-lowering response.
  • Its a completely different axis of variability, so were able to build models including both genetics and the gut microbiome to improve our statin response predictions, Wilmanski said.

Virtualitics AI Platform to Support Computational Biology Research on Long Covid Treatment Options

Retrieved on: 
Wednesday, March 30, 2022
Organization, Institute for Systems Biology, NASA, Diagnosis, Risk, Research, CSO, Systems biology, Genomics, Data analysis, CEO, California Institute for Quantitative Biosciences, Cell, Institute, COVID-19, Long COVID, Jet Propulsion Laboratory, AI, Technology, Proteomics, Patient, ISB, Pharmaceutical industry, Medical device

PASADENA, Calif., March 30, 2022 /PRNewswire/ -- Today, Virtualitics Inc, an advanced analytics and predictive AI company announced that the Institute for Systems Biology (ISB) will employ Virtualitics' AI platform to enable researchers to discover the connections between vast amounts of Covid-related data for a research study on Long Covid treatment options. The research builds on a recent Long Covid study by ISB published in the journal Cell that uncovered four risk factors, measured before or at COVID-19 diagnosis, that identify which patients are likely to develop Long Covid.

Key Points: 
  • PASADENA, Calif., March 30, 2022 /PRNewswire/ -- Today, Virtualitics Inc, an advanced analytics and predictive AI company announced that the Institute for Systems Biology (ISB) will employ Virtualitics' AI platform to enable researchers to discover the connections between vast amounts of Covid-related data for a research study on Long Covid treatment options.
  • The research builds on a recent Long Covid study by ISB published in the journal Cell that uncovered four risk factors, measured before or at COVID-19 diagnosis, that identify which patients are likely to develop Long Covid.
  • Virtualitics' patented visualizations makes advanced analytics accessible to non-data scientists and enables researchers to explore their research directly.
  • "The Virtualitics AI Platform accelerates product development for life sciences organizations," said Ciro Donalek, CSO and cofounder of Virtualitics.

Institute for Systems Biology (ISB) Study Shows Maternal COVID-19 Infection Increases Risks of Preterm Birth, Low Birth Weight and Stillbirth

Retrieved on: 
Thursday, January 13, 2022
Health, Consumer, Infectious Diseases, Women, Baby, Maternity, General Health, People, Vaccination, COVID-19, Research, Preterm birth, Gestational age, Vaccine, LinkedIn, Systems biology, Institute for Systems Biology, Severe acute respiratory syndrome coronavirus 2, Ageing, White, Health information management, BMI, Health, Pregnancy, Infection, ISB, YouTube, Paper, Doctor of Philosophy, MD, Multimedia, Risk, Cancer, Twitter, Stillbirth, Degenerative disease, Birth control, Animal, Pharmaceutical industry, Medicaid, Facebook

People who contracted COVID-19 while pregnant were more likely to have poor birth outcomes including preterm birth, small for gestational age, low birth weight, and stillbirth.

Key Points: 
  • People who contracted COVID-19 while pregnant were more likely to have poor birth outcomes including preterm birth, small for gestational age, low birth weight, and stillbirth.
  • View the full release here: https://www.businesswire.com/news/home/20220113005783/en/
    An Institute for Systems Biology-led study examined the electronic health records of more than 18,000 people with SARS-CoV-2 tests during pregnancy.
  • Researchers compared outcomes of unvaccinated people with a positive test during pregnancy 882 in total to those who tested negative.
  • Additionally, poor birth outcomes were present even if maternal COVID-19 didnt result in severe respiratory problems during infection.